ESMO 2019 — Niraparib effective in newly diagnosed advanced ovarian cancer

  • Michael Simm
  • Oncology Conference reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.


  • Niraparib monotherapy after first-line platinum-based chemotherapy “should be considered a new standard of care,” according to primary investigator A. González-Martin (Navarra University, Madrid).

Why this matters

  • Ovarian cancer (OC) is the leading cause of cancer death in women with recurrence rates up to 85% after standard first-line platinum-based chemotherapy.
  • Niraparib is the first oral PARP inhibitor approved as maintenance in recurrent OC for all patients, regardless of BRCA-status.

Study design

  • 728 patients with newly diagnosed OC at high risk for recurrence after response to first-line platinum-based chemotherapy were randomised to niraparib or placebo.
  • Planned interim analysis at 11% of expected data.
  • A test for homologous recombination was used. Progression-free survival (PFS) and overall survival (OS) were calculated for homologous recombination proficient and homologous recombination deficient patients separately.
  • Funding: GlaxoSmithKline.

Key results

  • After a median follow-up of 13.8 months, 37% of patients with niraparib continued treatment vs 28% of patients with placebo.
  • Median PFS overall with niraparib 13.8 months vs 8.2 months with placebo. In HR-deficient patients PFS with niraparib was 21.9 months vs 10.4 months with placebo (both P
  • OS at 2 years did not achieve statistical significance in the overall population (84% vs 77%).
  • Similarly, in homologous recombination-deficient 91% vs 85% had survived, and among homologous recombination-proficient patients survival rates were 81% vs 59%, but neither of those differences achieved statistical significance.


  • Interim analysis, short follow-up.
  • Comparison was with placebo.